CEPHALEXIN-AS cefalexin 500mg (as monohydrate) capsule blister pack

Land: Ástralía

Tungumál: enska

Heimild: Department of Health (Therapeutic Goods Administration)

Kauptu það núna

Download Opinber matsskýrsla (PAR)
30-11-2017

Virkt innihaldsefni:

cefalexin (Equivalent: cefalexin, Qty 500 mg)

Fáanlegur frá:

Medis Pharma Pty Ltd

INN (Alþjóðlegt nafn):

cefalexin

Lyfjaform:

Capsule

Samsetning:

Excipient Ingredients: microcrystalline cellulose; Gelatin; titanium dioxide; sunset yellow FCF; sodium lauryl sulfate; quinoline yellow aluminium lake; purified water; patent blue V; magnesium stearate; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; Shellac; strong ammonia solution; iron oxide black; potassium hydroxide

Stjórnsýsluleið:

Oral

Einingar í pakka:

20 capsules

Gerð lyfseðils:

(S4) Prescription Only Medicine

Ábendingar:

Treatment of the following bacterial infections when caused by susceptible strains of the designated micro-organisms. Respiratory tract infections: Strep. pneumoniae and group A beta-haemolytic streptococci. Although penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections (including the prophylaxis of rheumatic fever), cephalexin is generally effective in the eradication of streptococci from the nasopharynx. Substantial data establishing the efficacy of cephalexin in the subsequent prevention of rheumatic fever are not available at present. Bacterial sinusitis: Streptococci, Strep. pneumoniae and Staph. aureus (methicillin sensitive only). Otitis media: Strep. pneumoniae, staphylococci (methicillin sensitive only). Skin and skin structure infections: Staphylococci (methicillin sensitive only) and/or streptococci. Genitourinary tract infections, including acute prostatitis: E. coli, P. mirabilis and Klebsiella sp. The effectiveness of cephalexin in the treatment of bacterial infections of the brain and spinal column has not been established and CEPHALEXIN-AS is not indicated in these conditions (see CONTRAINDICATIONS). Note: Appropriate culture and susceptibility tests should be initiated prior to and during therapy to determine susceptibility of the causative organism to CEPHALEXIN-AS. Renal function studies should be performed when indicated.

Vörulýsing:

Visual Identification: Size '0' capsules with dark green cap imprinted with "500" in black ink and light green body.; Container Type: Blister Pack; Container Material: PVC/PVDC/Al; Container Life Time: 2 Years; Container Temperature: Store below 30 degrees Celsius

Leyfisstaða:

Licence status A

Leyfisdagur:

2008-06-24